KR102348939B1 - 면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법 - Google Patents

면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법 Download PDF

Info

Publication number
KR102348939B1
KR102348939B1 KR1020197012865A KR20197012865A KR102348939B1 KR 102348939 B1 KR102348939 B1 KR 102348939B1 KR 1020197012865 A KR1020197012865 A KR 1020197012865A KR 20197012865 A KR20197012865 A KR 20197012865A KR 102348939 B1 KR102348939 B1 KR 102348939B1
Authority
KR
South Korea
Prior art keywords
masp
antibody
fibrosis
seq
inhibitory
Prior art date
Application number
KR1020197012865A
Other languages
English (en)
Korean (ko)
Other versions
KR20190063475A (ko
Inventor
니겔 존 브룬스킬
그레고리 에이. 데모풀로스
톰 두들러
한스-윌헬름 슈웨블
Original Assignee
유니버시티 오브 레스터
오메로스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by 유니버시티 오브 레스터, 오메로스 코포레이션 filed Critical 유니버시티 오브 레스터
Publication of KR20190063475A publication Critical patent/KR20190063475A/ko
Application granted granted Critical
Publication of KR102348939B1 publication Critical patent/KR102348939B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197012865A 2016-10-13 2017-10-12 면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법 KR102348939B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US62/407,979 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/399,524 2017-01-05
US15/470,647 2017-03-27
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
US62/527,926 2017-06-30
PCT/US2017/056386 WO2018071701A1 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Publications (2)

Publication Number Publication Date
KR20190063475A KR20190063475A (ko) 2019-06-07
KR102348939B1 true KR102348939B1 (ko) 2022-01-12

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012865A KR102348939B1 (ko) 2016-10-13 2017-10-12 면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법

Country Status (18)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN110177557A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3039927C (fr)
CL (2) CL2019000909A1 (fr)
GE (1) GEP20247587B (fr)
IL (1) IL265981A (fr)
JO (1) JOP20190068A1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
PH (1) PH12019500711A1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532943A (ja) 2006-03-31 2009-09-10 イーストマン コダック カンパニー 多階調中間調スクリーン生成方法
JP2009532493A (ja) 2006-04-03 2009-09-10 ユニバーシティ オブ レスター Ｍａｓｐ−２依存性の補体活性化に関連する状態を処置するための方法
WO2015058143A1 (fr) * 2013-10-17 2015-04-23 Omeros Corporation Procédés de traitement d'états associés à une activation du complément dépendant de masp-2
US20150239985A1 (en) 2011-04-08 2015-08-27 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374819B1 (fr) * 2003-05-12 2017-03-22 Helion Biotech ApS Anticorps contre MASP-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
ES2617920T3 (es) * 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
WO2012100262A1 (fr) * 2011-01-21 2012-07-26 Fibrogen, Inc. Méthode thérapeutique utilisant un anticorps anti-ctgf
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) * 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532943A (ja) 2006-03-31 2009-09-10 イーストマン コダック カンパニー 多階調中間調スクリーン生成方法
JP2009532493A (ja) 2006-04-03 2009-09-10 ユニバーシティ オブ レスター Ｍａｓｐ−２依存性の補体活性化に関連する状態を処置するための方法
US20150239985A1 (en) 2011-04-08 2015-08-27 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
WO2015058143A1 (fr) * 2013-10-17 2015-04-23 Omeros Corporation Procédés de traitement d'états associés à une activation du complément dépendant de masp-2

Also Published As

Publication number Publication date
BR112019007426A2 (pt) 2019-07-02
CN116726163A (zh) 2023-09-12
NZ753260A (en) 2021-11-26
CN110177557A (zh) 2019-08-27
CA3039927A1 (fr) 2018-04-19
EP3525798A4 (fr) 2020-07-08
AU2017342428B2 (en) 2021-02-04
AU2017342428A1 (en) 2019-05-23
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
JP2019534271A (ja) 2019-11-28
EP3525798A1 (fr) 2019-08-21
ZA201902933B (en) 2023-05-31
MX2019004074A (es) 2019-06-10
PH12019500711A1 (en) 2019-11-18
JP6893554B2 (ja) 2021-06-23
IL265981A (en) 2019-06-30
MA46541A (fr) 2019-08-21
WO2018071701A1 (fr) 2018-04-19
JOP20190068A1 (ar) 2019-04-01
CA3039927C (fr) 2023-10-10
UA126908C2 (uk) 2023-02-22
CA3210384A1 (fr) 2018-04-19
SG11201902941UA (en) 2019-05-30
KR20190063475A (ko) 2019-06-07
GEP20247587B (en) 2024-01-25

Similar Documents

Publication Publication Date Title
AU2020201804B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
US20210355236A1 (en) Methods for inhibiting fibrosis in a subject in need thereof
US20210079116A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
KR20220152554A (ko) 코로나바이러스-유도된 급성 호흡 곤란 증후군의 치료 및/또는 예방을 위해 masp-2를 억제하는 방법
KR102348939B1 (ko) 면역글로불린 a 신증을 앓고 있는 인간 대상체에서 단백뇨를 감소시키는 방법
US12005117B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
EA043102B1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
OA19229A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy.

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant